NEWS

By: Dan Leonard, Executive Director, We Work For Health Kansas is both a driver and a beneficiary of the most sustained period of growth...

Roundtable Highlights How Strong IP Protections Drive Breakthroughs and Benefit Patients RALEIGH, NC (August 12, 2025) — On Tuesday,...

By: Tom Kowalski, Co-Chair, We Work For Health Recent efforts to revive the so-called “Most Favored Nation” (MFN) drug pricing policy...

The Bayh-Dole Act of 1980 enables universities to retain intellectual property rights to discoveries made with federal funding, spurring...

While some in Washington are proposing damaging drug pricing policies, including “Most Favored Nation,” China is gaining ground in...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health What do North Carolina’s incredible universities have in common, in...

A common depiction of a U.S. biopharmaceutical industry worker shows someone working alone in a sterile lab environment. They wear a...

By: Candace DeMatteis, JD MPH, Policy Director, We Work For Health Smart policymaking and American ingenuity have combined to create an...

American innovation has long been the envy of the world, built on a foundation of strong intellectual property protections,...

By Dan Leonard, Executive Director, We Work For Health Global innovation is a long-distance race. For decades, the United States has led...

WASHINGTON, D.C. (May 12, 2025) — We Work For Health released the following statement in response to the executive order signed Monday...

By: Dan Leonard, Executive Director, We Work For Health The Administration’s latest proposal to revive the Most Favored Nation (MFN) drug...

WASHINGTON, D.C. (May 5, 2025) — We Work For Health released the following statement in response to reports around foreign reference...

By Dan Leonard, Executive Director, WWFH The Inflation Reduction Act (IRA), signed into law in August 2022, contains a healthcare...

This Saturday, we observe World Intellectual Property Day , a moment to reflect on how intellectual property (IP) rights enable...

We Work For Health recently hosted a Congressional briefing about the IRA "pill penalty" and the importance of passing the Ensuring...

By Tom Kowalski, WWFH Co-Chair Chronic disease has contributed to declining life expectancy in the United States , a disturbing pattern...

We Work For Health released the following statement on the Trump Administration’s April 15 executive order regarding the Inflation...

Small-molecule drug investment has fallen 68%—and 74% for diseases mainly affecting Medicare patients—since the IRA was introduced FOR...

The lead sponsors of the Ensuring Pathways to Innovative Cures (EPIC) Act addressed a room full of Congressional office employees and...

Learn about the Inflation Reduction Act—and how it’s threatening America’s biopharmaceutical ecosystem and our nation’s Medicare-aged...

Innovation often comes in increments. The first smartphones could not record video or take front-facing photos, and there certainly was...

A new report highlights the significant investments and economic impact generated by clinical trials funded by the biopharmaceutical...

Legislation would address the “pill penalty” and strengthen U.S. leadership in pharmaceutical innovation. WASHINGTON, D.C. (March 6,...

Healthcare costs continue to be a significant concern for Americans. While policies like government price controls under the Inflation...

Small-molecule drugs, which typically come in pill or tablet form, have long been the backbone of modern medicine, treating everything...

Bipartisan legislation would correct the IRA’s “pill penalty,” which will have a chilling effect on the prescription drug ecosystem...

We Work For Health Executive Director Dan Leonard's recently wrote a letter to the White House, encouraging a pause in the implementation...

FOR IMMEDIATE RELEASE JAN. 17, 2025   WASHINGTON, DC (Jan. 17, 2025) – The Centers for Medicare and Medicaid Services’ (CMS) announcement...

Research firm Vital Transformation is preparing a new analysis about the impacts of the Inflation Reduction Act on biopharma investment,...

At We Work For Health (WWFH), our commitment to fostering health equity across the nation goes beyond advocacy—it extends to tangible,...

The biopharmaceutical industry is the backbone of America's innovative economy, supporting more than 4.9 million jobs across the United...

We Work For Health Executive Director Dan Leonard released the following statement in support of recently introduced legislation that...

As Congress returned to Washington, the Senate Judiciary Committee held a full committee hearing  to consider a number of critical bills...

Washington, DC  – New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation...

New research from the IQVIA Institute for Human Data Science further confirms what We Work For Health (WWFH) and others have warned...

The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, profoundly changed the...

Dear Chairman Sanders, Ranking Member Cassidy, and Members of the Committee:  The American medical innovation infrastructure that has...

As healthcare access and costs continue to dominate political conversations, the flaws in the Inflation Reduction Act are becoming...

In 1984, the Hatch-Waxman Act – formally known as the bipartisan Drug Price Competition and Patent Term Restoration Act  – established a...

During a recent We Work For Health roundtable with California Rep. Scott Peters, leaders across patient advocacy, biopharma, labor,...

While the 1980s is best remembered for its questionable fashion and cultural influence, two critical policies from early in the decade...

American innovation depends on a strong, robust intellectual property system that allows health care advances to save and enhance lives....

We Work For Health recently unveiled a new set of one-page resources designed to highlight the significant impact of the...

A version of this blog originally published as an op-ed in The Center Square in Arizona. We're sharing it here with additional updates...

Aug. 15, 2024 FOR IMMEDIATE RELEASE WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard issued the following statement...

The Biden administration this week is expected to claim victory on its stated goal of lowering drug prices for seniors. While the...

By Dan Leonard, WWFH Executive Director Intellectual property (IP) plays a crucial role in the success of the pharmaceutical and biotech...

On Monday, the Centers for Medicare and Medicaid Services (CMS) announced 2025 premiums for Medicare Part D plans will increase again....

Meena Seshamani, M.D., Ph.D. CMS Deputy Administrator and Director of the Center for Medicare Centers for Medicare & Medicaid Services...